NCT07504458 2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3 Recruiting
Quetzal Therapeutics
SDK Therapeutics, Inc.
Technische Universität Dresden
Children's Oncology Group
Gruppo Italiano Malattie EMatologiche dell'Adulto
First Affiliated Hospital Xi'an Jiaotong University
Peking University People's Hospital
Assistance Publique - Hôpitaux de Paris
National Cancer Institute (NCI)
Teva Branded Pharmaceutical Products R&D, Inc.